Krantz, D., Goetzl, L., Simpson, J.L., Thom, E., Zachary, J., Hallahan, T.W., et al. (2004) Association of Extreme First-Trimester Free Human Chorionic Gonadotropin-Beta, Pregnancy-Associated Plasma Protein A, and Nuchal Translucency with Intrauterine Growth Restriction and Other Adverse Pregnancy Outcomes. American Journal of Obstetrics Gynecology, 191, 1452-1458.
http://dx.doi.org/10.1016/j.ajog.2004.05.068

has been cited by the following article:

• TITLE: Maternal PAPP-A Levels at 11 - 13 Weeks of Gestation Predict Foetal and Neonatal Growth

  AUTHORS: M. Gentile, M. Schifano, S. Lunardi, C. Nanini, F. Moscuzza, C. Sergiampietri, M. Ciantelli, F. Monacci, A. Boldrini, C. Luchi, P. Ghirri

  KEYWORDS: Maternal Predictors, Foetal Growth, Neonatal Outcome

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.5 No.6, June 24, 2015

  ABSTRACT: Recent reports suggest that maternal serum levels of pregnancy-associated plasma protein A (PAPP-A) may predict perinatal outcome. PAPP-A is a syncytiotrophoblast derived protease for insulin-like growth factor binding protein (IGFBP4); its protease activity cleaves complexed growth factor binding protein increasing insulin-like growth factor I (IGF-I) bioavailability. The aim of our study was to evaluate the correlation between maternal PAPP-A serum levels and neonatal growth. We analysed 100 full term and preterm (30 - 36 weeks) small for gestational age (SGA) and adequate for gestational age (AGA) babies whose mothers had been tested for serum PAPP-A at 11 - 13 weeks of gestation. We found a significant positive correlation between maternal PAPP-A and neonatal weight, length, and head circumference at birth in both term and preterm infants. Low maternal PAPP-A serum levels (maternal PAPP-A